This press release was issued by Cytek Biosciences, Inc.

One year after opening its 8,500-square-foot Singapore facility, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) is marking a major milestone in its Asia-Pacific (APAC) expansion. Serving as a strategic hub supporting customers across APAC and worldwide, the Singapore facility has contributed to Cytek’s growth over the past 12 months, significantly enhancing Cytek’s manufacturing capacity, regional service and training capabilities, and reinforcing global supply chain resilience while helping mitigate geopolitical and trade-related risks.

As life sciences research continues to expand worldwide, Cytek’s Singapore operations stand as a critical global component of its regional manufacturing strategy, advancing scientific discovery and supporting sustained business growth in one of the fastest-growing regions for biomedical research.

Driven by the growing global use of cellular analysis in immunology, immuno-oncology, infectious diseases, cancer diagnosis and cancer drug development, Cytek’s Singapore expansion was designed to address rising demand for cell analysis solutions. Over the past year, the facility has enhanced production scalability and reduced delivery times in key markets. The site also features a dedicated service and training center that provides hands-on, regional access to Cytek instruments and advanced technical expertise in addition to its manufacturing operation.